Lack of response in nine patients with breast cancer treated with fibroblast interferon
β Scribed by U. Bruntsch; G. Groos; F. -J. Tigges; P. H. Hofschneider; W. M. Gallmeier
- Publisher
- Springer
- Year
- 1984
- Tongue
- English
- Weight
- 380 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
β¦ Synopsis
Nine patients with metastatic breast cancer were treated with a minimum of 6 x 106 U/day of t3-interferon (IFN-t3) for at least 6 weeks. In patients whose disease did not progress during this period treatment was continued to a maximum of 13 weeks, while in other patients doses were escalated. With daily treatments over 3 weeks the maximum tolerated dose was found to be around 60 x 106 U/day. Fever occurred regularly. The dose-limiting toxicities were granulocytopenia and increasing liver enzymes.
No objective remissions were observed. One patient showed stable disease after her cancer en cuirasse had rapidly progressed under chemotherapy.
One patient each with nasopharyngeal carcinoma and fibrous sarcoma were also treated without success.
IFN-fl at this moderately toxic dose given over a period of 6-13 weeks is of no clinical value in the treatment of metastatic breast cancer in women.
π SIMILAR VOLUMES
## Abstract The growth properties of fibroblasts from the thoracic skin of patients with mammary cancers were compared to those of fibroblastic cultures from patients with benign lesions or having undergone surgery for nonβneoplastic diseases. As expected, an inverse correlation was found between t
## Abstract ## BACKGROUND. Hypothyroidism is a potential complication after radiation therapy (RT) when treatment fields include the thyroid. The authors assessed risk of hypothyroidism in breast cancer patients who were receiving RT to a supraclavicular field, which typically includes a portion o